Karyopharm Therapeutics Azioni (NASDAQ: KPTI)

Ultime notizie per Karyopharm Therapeutics (NASDAQ:KPTI) Azioni

Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $4 to $5.

News

Price Target

Analyst Ratings

KPTI

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

2024&nbsp;Financial Outlook
Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:
<ul>
<li>Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.</li>
<li>U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.</li>
<li>R&amp;D and selling, general and administrative (SG&amp;A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.</li>
<li>The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Biotech

Earnings

Guidance

Health Care

General

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

WIIM

Karyopharm Therapeutics shares are trading higher after the company announced that, following the FDA feedback, it will be replacing TSS50, one of the co-primary endpoints in the Phase 3 SENTRY Trial with Abs-TSS.

<ul>
<li>Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA.</li>
<li>Abs-TSS measures the average improvement in patient symptom scores over 24 weeks relative to the patient's baseline symptom score.&nbsp;</li>
<li>Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint.</li>
<li>Promising Improvement in&nbsp;Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial.</li>
<li>Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025.</li>
</ul>
&nbsp;

Karyopharm Therapeutics Announced That, Following FDA Feedback, The Company Will Be Replacing TSS50, One Of The Co-primary Endpoints In The Phase 3 SENTRY Trial With Abs-TSS

<h3>Gainers</h3>
<ul>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 13.4% to $3.9 during Monday's after-market session. The company's market cap stands at $165.5 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares moved upwards by 10.45% to $0.52. The company's market cap stands at $20.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) shares rose 9.76% to $17.2. The company's market cap stands at $42.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) shares increased by 5.81% to $0.74. The company's market cap stands at $50.6 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 5.75% to $0.48. The market value of their outstanding shares is at $41.2 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 5.41% to $0.93. The company's market cap stands at $132.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares decreased by 15.4% to $14.0 during Monday's after-market session. The market value of their outstanding shares is at $830.4 million. </li>
<li>Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) stock decreased by 9.4% to $0.75. The market value of their outstanding shares is at $93.7 million. </li>
<li>Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) stock decreased by 7.57% to $33.0. The company's market cap stands at $996.8 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock decreased by 6.26% to $0.13. The market value of their outstanding shares is at $14.6 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 5.0% to $0.65. The company's market cap stands at $6.5 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock decreased by 5.0% to $0.72. The market value of their outstanding shares is at $34.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLM

BNGO

CGTX

IGMS

NIVF

OMIC

PNTG

RPTX

12 Health Care Stocks Moving In Monday's After-Market Session

Karyopharm Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kpti#NASDAQ">KPTI</a>) has been beaten down lately with too much selling pressure. While the stock has lost 12.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
<h2>Here is How to Spot Oversold Stocks</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Here&#39;s Why KPTI Could Experience a Turnaround</h2>
The RSI reading of 28.75 for KPTI is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for KPTI has increased 19.5%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, KPTI currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2332006/down-12-14-in-4-weeks-here-s-why-karyopharm-therapeutics-kpti-looks-ripe-for-a-turnaround?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2332006">To read this article on Zacks.com click here.</a>

Penny Stocks

Technicals

Small Cap

Markets

Trading Ideas

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and maintains $3 price target.

RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target

Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Outperform and lowers the price target from $8 to $5.

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5

Karyopharm Revises FY24 Total Revenue Outlook From $140M - $160M To $145M - $160M, Est $145.44M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 31.03 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $42.786 million which beat the analyst consensus estimate of $36.179 million by 18.26 percent. This is a 13.86 percent increase over sales of $37.579 million the same period last year.

Earnings Beats

Karyopharm Therapeutics Q2 2024 GAAP EPS $(0.20) Beats $(0.30) Estimate, Sales $42.786M Beat $36.179M Estimate

HC Wainwright &amp; Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and lowers the price target from $8 to $7.

HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

Events

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses from SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Offerings

Karyopharm Therapeutics Files For Shelf Registration Of Up To 45.8M Shares Of Common Stock By Selling Stockholders

Financing

Karyopharm Announces Refinancing Transactions $148M Of Existing Convertible Notes Due In 2025 To Be Exchanged for $111M Of New Convertible Notes Due In 2029 And Warrants, Issues New $100M Senior Secured Term Loan due in 2028a

Karyopharm Therapeutics Inc. 2024 Q3 - Results - Earnings Call Presentation

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), retaining the price target of ...

Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Karyopharm Therapeutics INC ( ($KPTI) ) has released its Q3 earnings. Here is a breakdown of the information Karyopharm Therapeutics INC presented ...

Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings

Barclays analyst Peter Lawson maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target of $5.00. Th...

Barclays Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)

Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) on November 6 and set a price t...

Strategic Clinical Advances and Revenue Growth Drive Buy Rating for Karyopharm Therapeutics

Jonathan Chang, an analyst from Leerink Partners, reiterated the Hold rating on Karyopharm Therapeutics (KPTI – Research Report). The associated pr...

Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), with a pri...

Karyopharm Therapeutics (KPTI) Receives a Buy from RBC Capital

Karyopharm (KPTI) announced that Kristin Abate, the company's Vice President, Accounting, Corporate Controller and Assistant Treasurer, has been ap...

Karyopharm appoints Kristin Abate as Chief Accounting Officer

The latest update is out from Karyopharm Therapeutics ( ($KPTI) ). Karyopharm Therapeutics Inc. has promoted Kristin Abate to Vice President, Chief...

Comments

Karyopharm Therapeutics

Notizie

Ultime notizie per Karyopharm Therapeutics (NASDAQ:KPTI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO